Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects

Acta Psychiatr Scand Suppl. 1999:395:118-28. doi: 10.1111/j.1600-0447.1999.tb05991.x.

Abstract

Cognitive impairment in schizophrenia must be seen as a disturbance of cortico-sub-cortical connectivity with a neurotransmitter imbalance in a circuitry system, which connects thalamic input with prefrontal processing and supplementary motor cortex and basal ganglia output. The concept of maze-solving behaviour as a continuous cognitive task evoking a conflict between prefrontal cortex and basal ganglia activity is explained and introduced to distinguish between the effects of D2 blocking agents and substances with a predominant 5HT2A receptor affinity, such as clozapine and risperidone. Complex mazes show a cognitive deficit in untreated schizophrenic patients that are impaired by conventional and improved by atypical antipsychotic substances. Processing speed improves most on clozapine, while parallel processing is best supported by the non-sedative atypical substance risperidone. Maze paradigms are presented.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents / pharmacology*
  • Brain / drug effects*
  • Brain / physiopathology
  • Cognition / drug effects
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / physiopathology
  • Decision Making / drug effects
  • Decision Making / physiology
  • Humans
  • Maze Learning / drug effects
  • Maze Learning / physiology
  • Models, Neurological
  • Neuropsychological Tests*
  • Neurotransmitter Agents / physiology
  • Problem Solving / drug effects
  • Problem Solving / physiology
  • Schizophrenia / drug therapy
  • Schizophrenia / physiopathology*
  • Schizophrenic Psychology*
  • Space Perception / drug effects
  • Space Perception / physiology

Substances

  • Antipsychotic Agents
  • Neurotransmitter Agents